Key Highlights

  • Shares were down 22.48 percent to USD 5.38 in pre-market trading on November 2, 2026.
  • A rival RRP immunotherapy received FDA accelerated approval, reported on October 30, 2026.
  • PAPZIMEOS net product sales were USD 74.7 million in the first half of 2026.
  • Total Revenue for the first half of 2026 was USD 78.2 million.
  • Third quarter results are due November 4, 2026, with a call at 4:30 PM ET.

What moved Precigen shares in pre-market trading

Precigen (NASDAQ:PGEN) was down 22.48 percent to USD 5.38 in pre-market trading on November 2, 2026. The decline follows news that a competing therapy for recurrent respiratory papillomatosis, or RRP, won FDA accelerated approval.

Reports on October 30, 2026 described a drop of about 27 percent in after-hours trading on that news.

The competing approval

Inovio Pharmaceuticals (NASDAQ:INO) received Accelerated Approval for Voceryq, a plasmid DNA based immunotherapy for adults with RRP, its first approved product. The approval rested on an open-label trial of 32 adults, in which 27 percent of those with a higher baseline surgery burden required no surgery in the first year.

The FDA said post-approval studies are needed to confirm clinical benefit. For Precigen, the approval introduces a direct competitor in the only indication it currently sells into.

Business background and recent results

Precigen is a commercial-stage biopharmaceutical company focused on precision medicines for difficult-to-treat diseases. Its pipeline spans immuno-oncology, autoimmune disorders and infectious diseases, with PRGN-3006 in acute myeloid leukemia listed as a lead program.

PAPZIMEOS was approved in August 2025 and shipments began in November 2025. PAPZIMEOS net product sales were USD 3.4 million in 2025, then USD 74.7 million in the first half of 2026, against total revenue of USD 78.2 million for that period.

Risks and valuation context

Precigen received an FDA platform technology designation for its AdenoVerse immunotherapy platform in early October 2026. The shares had risen strongly before the competitor news, with a close near USD 8.54 reported on October 2, 2026.

The company is dependent on one product, so competitive entry, pricing pressure or slower uptake could matter more than for a diversified business. The share price also carried a high sales multiple before this drop.

What to watch next

Precigen will release third quarter results on November 4, 2026 and host a call at 4:30 PM ET. Investors will look for PAPZIMEOS sales momentum, commentary on the new competitor and foreign regulatory plans.

Further detail on the competing product label and launch timing may also shape sentiment in the coming sessions.